Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).

NCT00356408 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00356408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00356408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
February 28, 2010
Enrollment
106 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease